Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease

被引:28
作者
Chen, Jiawei [1 ]
Mehta, Jawahar L. [1 ]
机构
[1] Univ Arkansas Med Sci, Div Cardiovasc Med, Little Rock, AR 72205 USA
关键词
D O I
10.1007/s11906-006-0010-2
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Hyperlipidemia and hypertension are frequently observed in patients with coronary artery disease. It has been proposed that an interaction between low-density lipoprotein, especially its oxidized form (ox-LDL), and renin-angiotensin system (RAS) activation is a major determinant of atherogenesis. Ox-LDL accumulation in the blood vessels enhances the expression and activation of RAS components; on the other hand, activation of RAS stimulates the accumulation of LDL and its oxidation into ox-LDL in the blood vessels. Individually ox-LDL and RAS activation induce oxidative stress and inflammatory cascade, whereas their combination exerts a synergistic effect. This concept of cross-talk between ox-LDL/hyperlipidemia and, RAS activation has been proven in laboratory animals. Clinical trials also suggest that blockade of hyperlipidemia and RAS may have a synergistic salutary effect on the outcome of patients with, hypertension and/or manifestations of atherosclerosis. This concept needs to be evaluated further in large clinical studies.
引用
收藏
页码:139 / 143
页数:5
相关论文
共 46 条
[1]  
Chen Jiawei, 2004, Indian Heart J, V56, P163
[2]   Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis - Studies with the combined use of rosuvastatin and candesartan [J].
Chen, JW ;
Li, DY ;
Schaefer, R ;
Mehta, JL .
ATHEROSCLEROSIS, 2006, 184 (02) :295-301
[3]   Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice - Novel insights into the role of RAS and dyslipidemid in atherogenesis [J].
Chen, JW ;
Li, DY ;
Schaefer, RF ;
Mehta, JL .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2004, 44 (04) :446-452
[4]   Angiotensin II regulation of collagen type I expression in cardiac fibroblasts -: Modulation by PPAR-γ ligand pioglitazone [J].
Chen, K ;
Chen, JW ;
Li, DY ;
Zhang, XJ ;
Mehta, JL .
HYPERTENSION, 2004, 44 (05) :655-661
[5]   Transforming growth factor β receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II [J].
Chen, K ;
Mehta, JL ;
Li, DY ;
Joseph, L ;
Joseph, J .
CIRCULATION RESEARCH, 2004, 95 (12) :1167-1173
[6]  
Chilton Robert J, 2004, J Am Osteopath Assoc, V104, pS5
[7]   Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation [J].
da Cunha, V ;
Tham, DM ;
Martin-McNulty, B ;
Deng, G ;
Ho, JJ ;
Wilson, DW ;
Rutledge, JC ;
Vergona, R ;
Sullivan, ME ;
Wang, YX .
ATHEROSCLEROSIS, 2005, 178 (01) :9-17
[8]   Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice - Evidence for a role in inflammation in angiotensin-induced vascular injury [J].
De Ciuceis, C ;
Amiri, F ;
Brassard, P ;
Endemann, DH ;
Touyz, RM ;
Schiffrin, EL .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (10) :2106-2113
[9]  
Ferrario Carlos M, 2004, Am J Ther, V11, P44, DOI 10.1097/00045391-200401000-00010
[10]   Thioredoxin reductase 1 is upregulated in atherosclerotic plaques:: Specific induction of the promoter in human macrophages by oxidized low-density lipoproteins [J].
Furman, C ;
Rundlöf, AK ;
Larigauderie, G ;
Jaye, M ;
Bricca, G ;
Copin, C ;
Kandoussi, AM ;
Fruchart, JC ;
Arnér, ESJ ;
Rouis, M .
FREE RADICAL BIOLOGY AND MEDICINE, 2004, 37 (01) :71-85